AlphAIAlphAI — Financial news for AI agents
aol.comOCT 11 min read$FHTX

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics (FHTX) stock fell 27.17% after ending its collaboration with Eli Lilly (LLY) and halting development of FHD-909. The company will focus on its wholly owned pipeline, including an EP300 degrader, and expects cash runway to extend into 2H 2029. FHTX reported $167.6M in cash as of June 30, 2026.

Original reporting
aol.com
Published Oct 1, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal — source image
Source · aol.com
Decision brief

The 30-second read

$FHTXBearishHigh
01

Why it matters

The partnership termination removes a major collaborator, likely reducing future cash inflows and increasing execution risk for the company's pipeline.

02

Market read

The news triggered a sharp intra‑day sell‑off, highlighting the materiality of partnership outcomes for small‑cap biotech valuations.

03

What to watch

Potential cost savings from the 40% workforce reduction and extended cash runway may mitigate some downside.

Relevance 7/10Novelty 7/10Timing: today

Background

Foghorn Therapeutics (FHTX) is a clinical‑stage biotech focused on epigenetic targets. The company previously partnered with Eli Lilly on SMARCA2/BRM programs.

Company-level read

Ticker impact

$FHTXBearishHigh confidence
Context

Foghorn Therapeutics announced it will not advance the Eli Lilly collaboration on FHD-909, causing the stock to fall 27% on the day.

Expected impact

likely continued downside as investors price in reduced pipeline prospects

Evidence & confidence

The news is a fresh, material development for a micro‑cap biotech; the stock already dropped sharply on the announcement.

Market effects

Sector

May dampen sentiment toward early‑stage biotech collaborations and could prompt re‑evaluation of similar partnership deals.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low; impact confined to the company and its immediate peers.

Counterpoint

What could challenge this read

If the wholly owned pipeline yields strong preclinical data, the stock could rebound on future upside potential.

Key entities

  • company
    Foghorn Therapeutics

    Clinical‑stage biotech developing epigenetic degrader programs.

  • company
    Eli Lilly & Co.

    Pharmaceutical partner that ended collaboration on FHD-909.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 2
$FHTXMed

Wedbush cuts Foghorn Therapeutics stock rating on drug setback

Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral, lowering its price target to $2.00. The move follows the discontinuation of FHD-909, a drug in collaboration with Eli Lilly, due to Phase 1 data. Foghorn is cutting 40% of its workforce and realigning operations. Other analysts have also lowered price targets, though some maintain positive ratings.

investing.com2 min
OCT 2
$FHTXLow

Guggenheim cuts Foghorn Therapeutics price target on drug setback

Guggenheim cut Foghorn Therapeutics' (FHTX) price target to $5.00 from $12.00, maintaining a Buy rating, after the company discontinued its lead drug program FHD-909. Foghorn and partner Eli Lilly halted the program due to insufficient efficacy in Phase 1 trials. The stock is down 16.6% over the past week, trading at $2.92. Analysts have mixed reactions, with some downgrading and others maintaining Buy ratings with adjusted targets.

investing.com2 min
OCT 1
$FHTXHigh

Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation

Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform after it and Eli Lilly discontinued the FHD-909 drug candidate due to poor efficacy. Shares fell 18% to $2.88, extending a 34% YTD decline. Citizens cited lack of near-term catalysts, noting shares trade at a 26% premium to cash reserves. InvestingPro analysis suggests undervaluation, while Stifel lowered its price target to $5.00 but maintained a Buy rating.

investing.com2 min